MYSM-1 suppresses migration and invasion in renal carcinoma through inhibiting epithelial-mesenchymal transition
- 230 Downloads
Renal cell carcinoma (RCC) is the most common malignant renal tumor and is prone to metastasis. However, the molecular variation and mechanism underlying renal cell carcinoma metastasis remains largely unknown. In our previous study, it was found that MYSM-1 was significantly downregulated in renal cell carcinoma tissues as compared with normal renal tissues without metastasis, using proteomics approach. Therefore, we hypothesized that MYSM-1 may suppress the metastasis of renal cell carcinoma in light of paucity of data regarding MYSM-1 in the cancers. In the present study, to confirm the expression status of MYSM-1 in renal cell carcinoma, immunohistochemistry with renal carcinoma tissue microarray was performed. It was shown that MYSM-1 was remarkably decreased in renal carcinoma tissues compared with paired normal control tissues; and that low expression of MYSM-1 was significantly associated with poor overall prognosis and metastasis. To investigate the biological roles of MYSM-1 in vitro in renal carcinoma cell lines, both knockdown using siRNA and over-expression were carried out. It was found that MYSM-1 could suppress the proliferation, migration, and invasion of renal carcinoma cells. In addition, we found that MYSM-1 could inhibit the epithelial-mesenchymal transition. Together, our results demonstrate that MYSM-1 could suppress the metastasis of renal carcinoma cells may be through inhibiting the epithelial-mesenchymal transition (EMT) process.
KeywordsRenal carcinoma MYSM-1 Metastasis Prognosis EMT
The work was supported by National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy project.
Conflict of interest
The authors declare that they have no competing interests.
- 1.G. Courthod, M. Tucci, M. Di Maio, G.V. Scagliotti, Papillary renal cell carcinoma: a review of the current therapeutic landscape, Crit Rev Oncol Hematol (2015).Google Scholar
- 4.Le G, Touzot F, Andre-Schmutz I, Lagresle-Peyrou C, France B, Kermasson L, et al. An in vivo genetic reversion highlights the crucial role of Myb-Like, SWIRM, and MPN domains 1 (MYSM1) in human hematopoiesis and lymphocyte differentiation. J Allergy Clin Immunol. 2015;6749(15):00800–3.Google Scholar
- 17.M.A. Helsby, J.R. Fenn, A.D. Chalmers, Reporting research antibody use: how to increase experimental reproducibility, F1000Res 2 (2013) 153.Google Scholar